Schizophrenia Research
Volume 76, Issue 1 , Pages 89-97 , 1 July 2005

Prevalence of and risk factors for tardive dyskinesia in a Xhosa population in the Eastern Cape of South Africa

  • Betty D. Patterson

      Affiliations

    • Rhodes University, Grahamstown, South Africa
    • North Dakota State University, College of Pharmacy, Fargo, ND, USA
    • Corresponding Author InformationCorresponding author. Present address: College of Pharmacy, North Dakota State University Box 5055 Fargo, ND 58105, USA. Tel.: +1 701 231 7603; fax: +1 701 231 7606.
    • ,
  • Dave Swingler

      Affiliations

    • Rhodes University, Grahamstown, South Africa
    • Fort England Hospital, Grahamstown, South Africa
    • ,
  • Sandi Willows

      Affiliations

    • Fort England Hospital, Grahamstown, South Africa

Received 2 July 2004 ,Revised 20 October 2004 ,Accepted 26 October 2004.

References 

  1. Adler LA, Rotrosen J, Edoson R, Lavori P, Lohr J, Hitzemann R, et al. Vitamin E treatment for tardive dyskinesia. Veterans Affairs Cooperative Study #394 Study Group. Arch. Gen. Psychiatry. 1999;56:836–841
  2. Ahrens TN, Sramek JJ, Herrera JM, Jewett CM, Alcorn VE. Pharmacy-based screening program for tardive dyskinesia. Drug. Intel. Clin. Pharm. 1988;22:205–208
  3. Atkins M, Burgess A, Bottomley C, Riccio M. Chlorpromazine equivalents: a consensus of opinion for both clinical and research applications. Psychiatr. Bull. 1997;21:224–226
  4. Baldessarini RJ. Clinical and epidemiologic aspects of tardive dyskinesia. J. Clin. Psychiatry. 1985;46(4 Pt 2):8–13
  5. Baldessarini RJ. In: Chemotherapy in Psychiatry. Boston: Harvard Univ. Press; 1985;p. 22
  6. Bassitt DP, Louza Neto MR. Clozapine efficacy in tardive dyskinesia in schizophrenic patients. Eur. Arch. Psychiatry Clin. Neurosci. 1998;248:209–211
  7. Binder RL, Kazamatsuri H, Nishimura T, McNiel DE. Smoking and tardive dyskinesia. Biol. Psychiatry. 1987;22:1280–1282
  8. Boomershine KH, Shelton PS, Boomershine JE. Vitamin E in the treatment of tardive dyskinesia. Ann. Pharmacother. 1999;33:1195–2202
  9. Brink S, Niehaus DHJ, Koen L, Muller J, Emsley RA. Tardive dyskinesia in a Xhosa population with schizophrenia: a descriptive study. Abstr. S. Afr. J. Psychiatry. 2003;9:46
  10. British National Formulary 44, 2002. British Medical Association, London, p178.
  11. Cavallaro R, Regazzetti MG, Mundo E, Brancato V, Smeraldi E. Tardive dyskinesia outcomes: clinical and pharmacologic correlates of remission and persistence. Neuropsychopharmacology. 1993;8:233–239
  12. Chakos MH, Alvir JM, Woerner MG, Koreen A, Geisler S, Mayerhoff D, et al. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Arch. Gen. Psychiatry. 1996;53:313–319
  13. Chong S, Mahendran R, Machin D, Chua H, Parker G, Kane J. Tardive dyskinesia among Chinese and Malay patients with schizophrenia. J. Clin. Psychopharmacol. 2002;22:26–30
  14. Chong S, Tan E, Tan C, Mythily MB. Smoking and tardive dyskinesia: lack of involvement of the CYP1A2 gene. J. Psychiatry Neurosci. 2003;28:185–189
  15. Chouinard G, Annable L, Mercier P, Ross-Chouinard A. A five-year follow-up study of tardive dyskinesia. Psychopharmacol. Bull. 1986;22:259–263
  16. Crane GE, Smeets RA. Tardive dyskinesia and drug therapy in geriatric patients. Arch. Gen. Psychiatry. 1974;30:341–343
  17. Emsley R, Turner HJ, Schronen J, Botha K, Smit R, Oosthuizen PP. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J. Clin. Psychiatry. 2004;65:696–701
  18. Gardos G, Casey DE, Cole JO, Perenyi A, Kocsis E, Arato M, et al. Ten-year outcome of tardive dyskinesia. Am. J. Psychiatry. 1994;151:836–841
  19. Gatere N, Othieno CJ, Kathuku DM. Prevalence of tardive dyskinesia among psychiatric in-patients at Mathari hospital, Nairobi. East Afr. Med. J. 2002;79:547–549
  20. Glazer WM. Review of incidence studies of tardive dyskinesia associated with typical antipsychotics. J. Clin. Psychiatry. 2000;61(Suppl. 4):15–20
  21. Glazer WM, Morgenstern H, Doucette JT. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. J. Clin. Psychiatry. 1993;54:133–139
  22. Glazer WM, Morgenstern H, Doucette J. Race and tardive dyskinesia among outpatients at a CMHC. Hosp. Commun. Psychiatry. 1994;45:38–42
  23. Goff DC, Henderson DC, Amico E. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Am. J. Psychiatry. 1992;149:1189–1194
  24. Holden TJ. Tardive dyskinesia in long-term hospitalised Zulu psychiatric patients. S. Afr. Med. J. 1987;71:88–90
  25. Jeste DV. Tardive dyskinesia rates with atypical antipsychotics in older adults. J. Clin. Psychiatry. 2004;65(Suppl. 9):21–24
  26. Jeste DV, Lacro JP, Palmer B, Rockwell E, Harris MJ, Caligiuri MP. Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients. Am. J. Psychiatry. 1999;156:309–311
  27. Kane JM. Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. J. Clin. Psychiatry. 2004;65(Suppl. 9):16–20
  28. Kane JM, Smith JM. Tardive dyskinesia. Prevalence and risk factors, 1959 to 1979. Arch. Gen. Psychiatry. 1982;39:473–481
  29. Kane JM, Woerner M, Borenstein M, Wegner J, Lieberman J. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol. Bull. 1986;22:254–259
  30. Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors. J. Clin. Psychopharmacol. 1988;8(4 Suppl.):52S–56S
  31. Kolakowska T, Williams AO, Ardern M, Reveley MA. Tardive dyskinesia in schizophrenics under 60 years of age. Biol. Psychiatry. 1986;21:161–169
  32. Lohr JB, Caliguiri MP. A double-blind placebo controlled study of vitamin E treatment of tardive dyskinesia. J Clin. Psychiatry. 1996;57:167–173
  33. Lohr JB, Kuczenski R, Niculescu AB. Oxidative mechanisms and tardive dyskinesia. CNS Drugs. 2003;17:47–62
  34. Lomond and Argyll Primary Care NHS Trust, 2001. Guidelines for psychiatrists on the prescription of antipsychotic drugs, including high doses for the treatment of schizophrenic illness. Website www.argyllnhs.org/uk/argyll-and-bute/mental_health.html, appendix 1 and 2.
  35. Menza MA, Grossman N, Van Horn M, Cody R, Forman N. Smoking and movement disorders in psychiatric patients. Biol. Psychiatry. 1991;30:109–115
  36. Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Arch. Gen. Psychiatry. 1993;50:723–733
  37. Naidu PS, Singh A, Kulkarni SK. Quercetin, a bioflavonoid, attenuates haloperidol-induced orofacial dyskinesia. Neuropharmacology. 2003;44:1100–1106
  38. Nilsson A, Waller L, Rosengren A, Adlerberth A, Wilhelmsen L. Cigarette smoking is associated with abnormal involuntary movements sin the general male population—a study of men born in 1933. Biol. Psychiatry. 1997;15:717–723
  39. Oosthuizen PP, Emsley RA, Maritz JS, Turner JA, Keyter N. Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol. J. Clin. Psychiatry. 2003;64:1075–1080
  40. Pandurangi A, Aderibigbe YA. Tardive dyskinesia in non-western countries: a review. Eur. Arch. Psychiatry Clin. Neurosci. 1995;246:47–52
  41. Richardson MA, Bevans ML, Read LL, Chao HM, Clelland JD, Suckow RF, et al. Efficacy of branched-chain amino acids in the treatment of tardive dyskinesia in men. Am. J. Psychiatry. 2003;160:1117–1124
  42. Schooler RN, Kane JM. Research diagnoses for tardive dyskinesia (letter). Arch. Gen. Psychiatry. 1982;39:309–311
  43. Seeman MV. Tardive dyskinesia: two-year recovery. Compr. Psychiatry. 1981;22:189–192
  44. Soares KC, McGrath JJ. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst. Rev. 2001;4:CD000209
  45. Sramek J, Roy S, Ahrens T, Pinanong P, Cutler NR, Pi E. Prevalence of tardive dyskinesia among three ethnic groups of chronic psychiatric patients. Hosp. Commun. Psychiatry. 1991;42:590–592
  46. Waddington JL, Youssef HA, Kinsella A. Cognitive dysfunction in schizophrenia followed up over 5 years and its longitudinal relationship to the emergence of tardive dyskinesia. Psychol. Med. 1990;20:835–842
  47. Woerner MG, Alvir JM, Saltz BL, Lieberman JA, Kane JM. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am. J. Psychiatry. 1998;155:1521–1528
  48. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J. Clin. Psychiatry. 2003;64:663–667
  49. Wszola BA, Newell KM, Sprague RL. Risk factors for tardive dyskinesia in a large population of youths and adults. Exp. Clin. Psychopharmacol. 2001;9:285–296
  50. Wyatt RJ. In: Practical Psychiatric Practice. 2nd edn.. Arlington: American Psychiatric Publishing; 1998;p. 01–26
  51. Yassa R, Nair V. The association of tardive dyskinesia and pseudoparkinsonism. Prog. Neuro-psychopharmacol. Biol. Psychiatry. 1988;12:909–914
  52. Yassa R, Nair V, Schwartz G. Tardive dyskinesia. A two-year follow-up study. Psychosomatics. 1984;25:852–855
  53. Yassa R, Lal S, Korpassy A, Ally J. Nicotine exposure and tardive dyskinesia. Biol. Psychiatry. 1987;22:67–72
  54. Ziedonis DM, Kosten TR, Glazer WM, Frances RJ. Nicotine dependence and schizophrenia. Hosp. Commun. Psychiatry. 1994;45:204–206

PII: S0920-9964(04)00401-3

doi: 10.1016/j.schres.2004.10.009

Schizophrenia Research
Volume 76, Issue 1 , Pages 89-97 , 1 July 2005

Article Tools